Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
The president said the new duties would “come shortly” in a speech on Tuesday, potentially joining levies specific to other sectors such as cars and auto parts.